For about 20 years, healthcare professionals have been unable to offer patients any new specific treatments for migraine. Excitingly, this may be about to change.
Recent research has shown that migraines are correlated with significant increases in the activity of Calcitonin Gene-Related Peptide (CGRP) and that when it is regulated by blocking the receptor, the frequency and intensity of migraine is significantly reduced. In some patients, migraine has been abolished for up to six months following the injection of a CGRP blocker.
Now clinicians and scientists worldwide are exploring the science of CGRP – a 37-amino acid peptide – and evaluating the therapeutic efficacy and safety of CGRP-binding antibodies.
Further readingKarsan N, Goadsby PJ. Calcitonin gene-related peptide and migraine. Curr Opin Neurol 2015;28:250-4. PUBMED 25887765
Edvinsson L. The journey to establish CGRP as a migraine target: a retrospective view. Headache 2015;55:1249-55. PUBMED 26368117
An important role for the CGRP ForumRecognising the need for an independent source of information and analysis of these developments, a global group of experts has created the CGRP Education and Research Forum.
To expand understanding of the role of CGRP in migraine and its therapeutic potential.
To develop educational alliances with other international societies to widely disseminate knowledge about CGRP as a novel target in migraine.
To facilitate expert meetings that will help to identify gaps in knowledge in this field and stimulate further research into migraine.
Full Editorial Board »